Sunitinib News and Research

RSS
Sunitinib malate is approved by the Food and Drug Administration (FDA) to treat a type of stomach cancer called gastrointestinal stromal tumor (GIST). It is used in patients whose condition has become worse while taking another drug called imatinib mesylate or who are not able to take imatinib mesylate.
Two widely used targeted therapy drugs not effective in preventing return of kidney cancer

Two widely used targeted therapy drugs not effective in preventing return of kidney cancer

Study results report no benefit from use of sunitinib, sorafenib among patients with kidney cancer

Study results report no benefit from use of sunitinib, sorafenib among patients with kidney cancer

Quality of life maintained during mRCC TKI therapy

Quality of life maintained during mRCC TKI therapy

TNF-α key player in RCC progression

TNF-α key player in RCC progression

Immature blood vessels linked to poor sunitinib response

Immature blood vessels linked to poor sunitinib response

First-line sunitinib superior to everolimus for metastatic RCC

First-line sunitinib superior to everolimus for metastatic RCC

Adopting a comprehensive and integrative healing strategy for cancer

Adopting a comprehensive and integrative healing strategy for cancer

Cytoreductive nephrectomy can benefit patients with mRCC

Cytoreductive nephrectomy can benefit patients with mRCC

Alternative sunitinib treatment schedules for mRCC may be worth the switch

Alternative sunitinib treatment schedules for mRCC may be worth the switch

Protein may predict outcome of targeted mccRCC therapy

Protein may predict outcome of targeted mccRCC therapy

Elderly mRCC patients should not be excluded from targeted therapy option

Elderly mRCC patients should not be excluded from targeted therapy option

Partial nephrectomy predicts survival among metastatic RCC patients

Partial nephrectomy predicts survival among metastatic RCC patients

Genetic variants alter chance of sunitinib dose reduction

Genetic variants alter chance of sunitinib dose reduction

18F-FGD-PET measures predict mRCC TKI response

18F-FGD-PET measures predict mRCC TKI response

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Sunitinib-related fatigue occurs early then tails off during RCC treatment

Sunitinib-related fatigue occurs early then tails off during RCC treatment

Multiple lines of targeted therapy extend life for mRCC patients

Multiple lines of targeted therapy extend life for mRCC patients

Altering sunitinib dosing schedule improves tolerability

Altering sunitinib dosing schedule improves tolerability